CAREDX INCCDNA
ASignal's systematic analysis rates CDNA as Neutral.
Reflects the latest available analysis · analyzed Oct 15, 2026
The case on CDNA
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong revenue growth (52.2% YoY)
- High gross margin (70.58%)
- Exceptional ROE (29.49%)
- Low debt-to-equity ratio (0.05x)
- Strong cash position with $373.64M in cash
- Free cash flow of $112.16M
- Negative price momentum
- MACD below signal line
- High forward P/E (50.15x) suggesting valuation risk
- Very low operating margin (0.19%)
- Negative ROA (-0.25%)
- No Reddit sentiment data available
See the full verdict on CDNA
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes CDNA
Most investors never get a second opinion, let alone several. ASignal runs CDNA past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.